We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Medifast's Coaching Model Complement GLP-1 Weight-Loss Drugs?
Read MoreHide Full Article
Key Takeaways
MED is positioning Trilivy alongside GLP-1 drugs, emphasizing nutrition, coaching and metabolic health.
MED coach productivity reached 54% in Q3, improving for the fourth consecutive quarter year over year.
MED's Reset 5 & 1 plan reduced visceral fat 14% while preserving 98% of lean mass over 16 weeks.
Medifast, Inc. (MED - Free Report) continues to position its coaching-led metabolic health platform, Trilivy, as a complementary solution to GLP-1 weight-loss medications rather than competing directly with them.Management believes sustainable weight management requires lifestyle changes, nutrition and ongoing coaching support alongside medication. The company is shifting its focus beyond weight loss toward metabolic health, with greater emphasis on preserving lean muscle, reducing fat and supporting long-term metabolic flexibility.
Medifast noted that its coaches are increasingly working with clients who use GLP-1 medications. Conversations are shifting from the amount of weight lost to the quality of weight loss, including the preservation of lean mass and skeletal muscle. Management believes GLP-1 medications can encourage people to begin their health journeys, while nutritional guidance and coaching support remain important for achieving sustainable, long-term results.
Trilivy's three-phase metabolic health system, comprising Reset, Refine and Renew, is designed to support clients throughout their health journeys, including those taking GLP-1 medications, transitioning off them or not using them. The company also highlighted an independent clinical study in which its Reset 5 & 1 plan reduced visceral fat by 14% while retaining 98% of lean mass over 16 weeks.
Coach productivity also improved year over year for the fourth consecutive quarter, reaching 54% in the third quarter of fiscal 2026 and increasing an estimated 8% sequentially. Medifast's coaching-led model and strategy of complementing GLP-1 treatments could strengthen its position in the metabolic health market. Continued adoption of Trilivy may expand MED’s client base, deepen engagement and support sustainable growth.
The Zacks Rundown for MED
The Zacks Rank #3 (Hold) company's shares have gained 8.3% in the past three months against the industry’s decline of 1.1%.
Image Source: Zacks Investment Research
From a valuation standpoint, MED trades at a forward price-to-sales ratio of 0.49, lower than the industry’s average of 0.80.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MED’s current fiscal year bottom line calls for a year-over-year decline of 26.8%, whereas the same for next fiscal year earnings suggests 54.8% growth year over year.
Image Source: Zacks Investment Research
Stocks to Consider
Some better-ranked stocks have been discussed below:
Lamb Weston Holdings, Inc. (LW - Free Report) engages in the production, distribution and marketing of frozen potato products in the United States, Canada, Mexico and internationally. LW currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Lamb Weston's current fiscal-year sales indicates a decline of 0.5%, and the same for earnings indicates growth of 7.6% from the prior-year levels. Lamb Weston delivered a trailing four-quarter earnings surprise of 22.1%, on average.
B&G Foods, Inc. (BGS - Free Report) manufactures, sells and distributes a portfolio of shelf-stable and frozen foods and household products. BGS currently carries a Zacks Rank #2 (Buy).
The Zacks Consensus Estimate for B&G Foods’ current fiscal-year earnings implies growth of 11.8% from the year-ago actuals. BGS delivered a trailing four-quarter negative earnings surprise of 13.3%, on average.
The J. M. Smucker Company (SJM - Free Report) operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address obesity and support a healthy life in the United States. SJM currently carries a Zacks Rank of 2.
The Zacks Consensus Estimate for SJM's current fiscal-year sales indicates a decline of 1.4%, and the same for earnings indicates growth of 17.1% from the prior-year levels. SJM delivered a trailing four-quarter earnings surprise of 13.8% on average.
Image: Bigstock
Can Medifast's Coaching Model Complement GLP-1 Weight-Loss Drugs?
Key Takeaways
Medifast, Inc. (MED - Free Report) continues to position its coaching-led metabolic health platform, Trilivy, as a complementary solution to GLP-1 weight-loss medications rather than competing directly with them.Management believes sustainable weight management requires lifestyle changes, nutrition and ongoing coaching support alongside medication. The company is shifting its focus beyond weight loss toward metabolic health, with greater emphasis on preserving lean muscle, reducing fat and supporting long-term metabolic flexibility.
Medifast noted that its coaches are increasingly working with clients who use GLP-1 medications. Conversations are shifting from the amount of weight lost to the quality of weight loss, including the preservation of lean mass and skeletal muscle. Management believes GLP-1 medications can encourage people to begin their health journeys, while nutritional guidance and coaching support remain important for achieving sustainable, long-term results.
Trilivy's three-phase metabolic health system, comprising Reset, Refine and Renew, is designed to support clients throughout their health journeys, including those taking GLP-1 medications, transitioning off them or not using them. The company also highlighted an independent clinical study in which its Reset 5 & 1 plan reduced visceral fat by 14% while retaining 98% of lean mass over 16 weeks.
Coach productivity also improved year over year for the fourth consecutive quarter, reaching 54% in the third quarter of fiscal 2026 and increasing an estimated 8% sequentially. Medifast's coaching-led model and strategy of complementing GLP-1 treatments could strengthen its position in the metabolic health market. Continued adoption of Trilivy may expand MED’s client base, deepen engagement and support sustainable growth.
The Zacks Rundown for MED
The Zacks Rank #3 (Hold) company's shares have gained 8.3% in the past three months against the industry’s decline of 1.1%.
Image Source: Zacks Investment Research
From a valuation standpoint, MED trades at a forward price-to-sales ratio of 0.49, lower than the industry’s average of 0.80.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MED’s current fiscal year bottom line calls for a year-over-year decline of 26.8%, whereas the same for next fiscal year earnings suggests 54.8% growth year over year.
Image Source: Zacks Investment Research
Stocks to Consider
Some better-ranked stocks have been discussed below:
Lamb Weston Holdings, Inc. (LW - Free Report) engages in the production, distribution and marketing of frozen potato products in the United States, Canada, Mexico and internationally. LW currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Lamb Weston's current fiscal-year sales indicates a decline of 0.5%, and the same for earnings indicates growth of 7.6% from the prior-year levels. Lamb Weston delivered a trailing four-quarter earnings surprise of 22.1%, on average.
B&G Foods, Inc. (BGS - Free Report) manufactures, sells and distributes a portfolio of shelf-stable and frozen foods and household products. BGS currently carries a Zacks Rank #2 (Buy).
The Zacks Consensus Estimate for B&G Foods’ current fiscal-year earnings implies growth of 11.8% from the year-ago actuals. BGS delivered a trailing four-quarter negative earnings surprise of 13.3%, on average.
The J. M. Smucker Company (SJM - Free Report) operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address obesity and support a healthy life in the United States. SJM currently carries a Zacks Rank of 2.
The Zacks Consensus Estimate for SJM's current fiscal-year sales indicates a decline of 1.4%, and the same for earnings indicates growth of 17.1% from the prior-year levels. SJM delivered a trailing four-quarter earnings surprise of 13.8% on average.